Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management.
Video content above is prompted by the following:
Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More